CONTINUED... Read this and more news for Oncolytics Biotech at: In other recent industry developments and happenings in the m ...

Super Micro Computer Inc SMCI gained 12.3% to $53.80 amid positive sentiment ahead of its annual report filing deadline on Feb 25. The shares are also rising following its upbeat FY2026 revenue ...

Baird says Allogene Therapeutics’s (ALLO) cemacabtagene ansegedleucel data update is positive. The firm is “quite encouraged” by the update, ...

In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Allogene Therapeutics (ALLO – Research ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

Detailed price information for Allogene Therapeutics Inc (ALLO-Q) from The Globe and Mail including charting and trades.

Allogene Therapeutics, Inc. (NASDAQ:ALLO), a biotechnology company specializing in the development of allogeneic CAR T cell therapies, stands at a critical juncture in its journey to bring innovative ...

Shares of US clinical-stage biotech Allogene Therapeutics rocketed 41% to $1.99 on Friday, as it announced the publication of ...

Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...